A person walks past the Pfizer building in New York City, March 2, 2021.
Carlo Allegri | Reuters
Pfizer said Wednesday it is raising the 2021 sales forecast of its Covid-19 vaccine to $33.5 billion from $26 billion, as the delta variant spreads and scientists debate whether people will need booster shots.
In releasing its second-quarter financial results, the company said it sold $7.8 billion in Covid shots in the second quarter. It also reported earnings and revenue that beat Wall Street’s expectations.
Here’s how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted EPS: $1.07 per share vs. 97 cents per share
- Revenue: $18.98 billion vs. $18.74 billion
It expects an adjusted pretax profit in the high 20% range of revenue for the vaccine.
This is a developing story. Please check back for updates.